(AGENPARL) - Roma, 13 Novembre 2024 - (AGENPARL) – mer 13 novembre 2024 Lund, Sweden, 13 November, 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm:
HNSA) today announced it will attend Jefferies London Healthcare Conference 19
-21 November. Hansa management will be available for meetings at the conference.
If you are interested in meeting with the management team, please contact Hansa
To learn more about Hansa Biopharma see the latest Corporate
Presentation here. (https://www.hansabiopharma.com/files/Presentations/2024/Hansa
Biopharma_CorporatePresentation_Oct2024_4.pdf) The latest investor presentation
can be
Q3-24_EarningsPresentation.pdf).
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. Hansa Biopharma has
developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme
therapy, which has been shown to enable kidney transplantation in highly
sensitized patients. Hansa Biopharma has a rich and expanding research and
development program based on the Company’s proprietary IgG-cleaving enzyme
technology platform, to address serious unmet medical needs in transplantation,
autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund,
Sweden, and has operations in Europe and the U.S. The company is listed on
Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com
and follow us on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/sZmjVQ85GMc76gXbsbXz7gvPGPrsmYBKKQKFBkuFgNjP1tePKXpsLwMPP652gRSzxYoqpNLqk3tV6EQeoY8vkhHQipxhF2KoPNMuZkHPW1JX5.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/sZmjVQ85GMc76gXbsbXz7gvPGPrsmYBKKQKFBkuFgNjP1tePKXpsLwMPP652gRSzxYoqpNLqk3tV6EQeoY8vkhHQipxhF2KoPNMuZkHPW1JX5.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content